Voyager director granted options for 30,000 shares

Voyager Therapeutics, Inc. director Nancy Vitale received a grant of stock options covering 30,000 shares of common stock.

Rhea-AI Filing Summary

Voyager Therapeutics, Inc. director Nancy Vitale received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $3.43 per share and expire on June 9, 2036. All 30,000 underlying shares vest on the earlier of one year from the grant date or the next annual meeting of stockholders, subject to her continued service as a director. Following this grant, she holds options for 30,000 shares directly.

Insider Trade Summary

Grant/Award: 30,000 shares

Grant/Award 1 txn

Insider Vitale Nancy

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	30,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 30,000 contracts (Direct)

Footnotes (1)

1. F1. This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director.

Key Figures

Option grant size: 30,000 shares Exercise price: $3.43 per share Expiration date: June 9, 2036 +2 more

5 metrics

Option grant size 30,000 shares Stock option covering common stock granted to director

Exercise price $3.43 per share Strike price of the stock option

Expiration date June 9, 2036 Option expiration for the 30,000-share grant

Shares underlying option 30,000 shares Common stock underlying the derivative security

Shares held after transaction 30,000 options Total derivative position following the grant

Key Terms

Stock Option (Right to Buy), 2025 Stock Incentive Plan, director compensation policy, vesting commencement date, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

2025 Stock Incentive Plan financial

"This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc."

director compensation policy financial

"in accordance with its director compensation policy."

vesting commencement date financial

"The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date."

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

annual meeting of stockholders financial

"vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Voyager Therapeutics (VYGR) report for Nancy Vitale?

Voyager Therapeutics reported that director Nancy Vitale received a stock option grant for 30,000 shares. The award is a compensation-related grant, not an open-market trade, and reflects standard equity-based director compensation under the company’s 2025 Stock Incentive Plan.

What are the key terms of Nancy Vitale’s 30,000-share option at Voyager Therapeutics (VYGR)?

Nancy Vitale’s option covers 30,000 shares of common stock at an exercise price of $3.43 per share. The option was granted under the 2025 Stock Incentive Plan and expires on June 9, 2036, providing a long-dated equity incentive linked to the company’s future performance.

How do Nancy Vitale’s Voyager Therapeutics (VYGR) options vest?

All 30,000 shares underlying Nancy Vitale’s option vest on the earlier of the one-year anniversary of the grant date or the next annual stockholder meeting. Vesting is conditioned on her continued service as a director through that date, aligning the award with ongoing board service.

Is Nancy Vitale’s Voyager Therapeutics (VYGR) option grant an open-market purchase or sale?

The transaction is a grant of stock options as compensation, not an open-market purchase or sale. It was reported with code A, indicating a grant or award acquisition, so no shares were bought or sold in the public market in this Form 4 transaction.

How many Voyager Therapeutics (VYGR) options does Nancy Vitale hold after this grant?

After the reported transaction, Nancy Vitale holds stock options for 30,000 shares of Voyager Therapeutics common stock. These options are held directly and represent her recorded derivative position in this filing, all from the single compensation-related grant on the transaction date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/11/2026 - 04:04 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vitale Nancy

(Last) (First) (Middle)

C/O VOYAGER THERAPEUTICS, INC.

75 HAYDEN AVENUE

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Voyager Therapeutics, Inc. [ VYGR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.43	06/09/2026		A		30,000		(1)	06/09/2036	Common Stock	30,000	$0	30,000	D

Explanation of Responses:

1. This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director.

Remarks:

Exhibit 24: Power of Attorney

	/s/ Gregory L. Shiferman, as Attorney-in-Fact for Nancy Vitale	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)